Medical Center Evrohealth EOOD
- Address
- 3, Sv. Georgi Sofiyski Str., 1606 Sofia, Bulgaria
Digestive System Diseases and Nutritional and Metabolic Diseases
At Medical Center Evrohealth EOOD in Sofia, clinical research in these areas focuses on conditions such as severe hypertriglyceridemia and hepatic impairment. The trials are designed to assess whether new therapies can improve metabolic control and better understand how liver function may affect treatment safety and effectiveness.
- Testing a potential treatment for severe hypertriglyceridemia
- Evaluating the impact of hepatic impairment on treatment response
- Assessing safety and tolerability in metabolic and liver-related conditions
These studies reflect a strong interest in improving care for patients with complex metabolic and digestive system disorders.
Immune System Diseases
Research in immune-mediated diseases at this site includes studies of primary discoid lupus erythematosus, with a focus on reducing active disease symptoms and exploring new options for disease control. The work aims to improve treatment effectiveness for patients living with chronic inflammatory conditions.
- Studying therapy options for primary discoid lupus erythematosus
- Measuring changes in active disease activity
- Evaluating whether a new approach can improve immune disease management
This area highlights ongoing efforts to advance care for people affected by autoimmune skin and systemic immune disorders.
Skin and Connective Tissue Diseases
Clinical trials in this therapeutic area at Medical Center Evrohealth EOOD are centered on hidradenitis suppurativa, a painful chronic skin condition. The research is aimed at determining whether new treatments can lessen symptoms, improve skin health, and provide better disease control compared with standard care or placebo.
- Evaluating treatment effectiveness in hidradenitis suppurativa
- Assessing symptom improvement in moderate to severe disease
- Supporting development of better options for chronic inflammatory skin disease
These studies contribute to broader efforts in dermatology and connective tissue disease research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Evrohealth EOOD
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (SHTG) | Ionis Pharmaceuticals Inc. | Phase III | Not Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Daxdilimab | 1 | Unknown | 2023-05-16 | 2023-05-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.